Important

Research Use Notice

All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Do not administer these products to humans or animals.

Product Documentation

Details, specifications, and documents

Description

Pancragen 20 mg: research material

Buy Pancragen 20 mg for laboratory research, supplied as lyophilized powder in one boxed 3 mL vial.

Published Pancragen research describes Lys-Glu-Asp-Trp, abbreviated KEDW, in experiments on pancreatic-cell differentiation. Sequence notation and terminal chemistry are important parts of those research methods.

Choose the material and presentation

This presentation contains a labeled 20 mg of material. The 3 mL figure is the vial capacity, not a supplied liquid volume or solution concentration.

A published Pancragen study explicitly identifies an amidated form, KEDW-NH2. A free-acid terminus is chemically different. Terminal chemistry and counterions determine which molecular-weight reference applies. Record those details alongside the sequence when comparing laboratory methods.

Pancragen in pancreatic-cell research

A 2012 cell-culture study examined short peptides in several tissue models. The Pancragen experiments concerned human embryonic pancreatic cells and differentiation-associated markers, including CXCL12 and Hoxa3.

The authors reported lower marker expression in later-passage cultures and a more pronounced peptide-associated response in those cultures. Here, culture aging means repeated laboratory passage. It is not a measurement of pancreatic function or aging in people.

These observations concern differentiation-associated markers in the cell cultures studied. The study compared distinct peptides in different tissues, so results from its bronchial-cell or fibroblast experiments should not be assigned to Pancragen.

Product records

Open the Documents tab for the product files currently provided with this listing. Check that each record identifies the material and presentation you need. Where an experiment requires a batch-specific certificate, request the applicable report and confirm its lot match before relying on it.

Identity, chromatographic purity and measured content are different specifications. Storage and handling requirements also need material-specific support; another supplier’s solvent instructions or expiry period should not be treated as this vial’s specification.

Additional information

Applications

Laboratory research

Format

Lyophilized powder

Appearance

Lyophilized powder

Safety Information

See Documents for available product files.

COA & Documents

Independent lot testing

Pancragen 20mg Certificate of Analysis

This product has featured batch-specific third-party laboratory documentation. The Pure Lab Peptides summary presents selected source-report fields in a consistent format; the linked original laboratory report controls if any information differs.

Lot number
94940
Report number
40172
Date tested
September 23, 2026
Reported purity
99.001%
Labeled content
20 mg
DOWNLOADABLE RESOURCES

Product documents

Product information and laboratory resources. For lot-specific results, use the COA above.

PDF

Product & packaging information

Labeled amount, physical form and packaging for Pancragen 20mg.

Revision 0.4 · 2026-10-05Download PDF
PDF

Laboratory handling guide

General guidance for applicable lyophilized research materials. Not a product-specific SDS.

Revision 1.0 · 2026-09-22Download PDF
General guides & resources

Need Assistance?

Questions about product documentation?

Contact our support team for help with product records, lot information, orders or certificate verification.

Contact Support